GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (CHIX:SDZz) » Definitions » Cash-to-Debt

Sandoz Group AG (CHIX:SDZZ) Cash-to-Debt : 0.24 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sandoz Group AG's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.24.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Sandoz Group AG couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Sandoz Group AG's Cash-to-Debt or its related term are showing as below:

CHIX:SDZz' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.22   Med: 0.23   Max: 0.24
Current: 0.24

During the past 2 years, Sandoz Group AG's highest Cash to Debt Ratio was 0.24. The lowest was 0.22. And the median was 0.23.

CHIX:SDZz's Cash-to-Debt is ranked worse than
72.83% of 1001 companies
in the Drug Manufacturers industry
Industry Median: 0.96 vs CHIX:SDZz: 0.24

Sandoz Group AG Cash-to-Debt Historical Data

The historical data trend for Sandoz Group AG's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Sandoz Group AG Cash-to-Debt Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Cash-to-Debt
0.22 0.24

Sandoz Group AG Quarterly Data
Dec22 Dec23
Cash-to-Debt 0.22 0.24

Competitive Comparison of Sandoz Group AG's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Cash-to-Debt falls into.


Sandoz Group AG Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Sandoz Group AG's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=959.063 / (279.33 + 3658.104)
=0.24

Sandoz Group AG's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=959.063 / (279.33 + 3658.104)
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG  (CHIX:SDZz) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Sandoz Group AG Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (CHIX:SDZZ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (CHIX:SDZz) » Definitions » Cash-to-Debt
Comparable Companies
Traded in Other Exchanges
SDZXF:USA SDZNY:USA D8Y0:Germany SDZ:Switzerland
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Website
https://www.sandoz.com
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (CHIX:SDZZ) Headlines

No Headlines